We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00673010
Recruitment Status : Active, not recruiting
First Posted : May 7, 2008
Last Update Posted : February 26, 2018
Gustave Roussy, Cancer Campus, Grand Paris
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:

One of the most effective treatments for metastases from thyroid cancer is a form of radioactive iodine known as 131-I. For more than 50 years, 131-I has been used to find and destroy thyroid cancer cells that have spread to other parts of the body. In many cases this treatment destroys the metastatic cells. However, in some patients it does not appear to work completely. This study is designed to use a slightly different form of radioactive iodine (called 124-I) which can precisely predict the amount of radiation that each metastatic lesion will receive.

124-I was developed at Memorial Sloan-Kettering in the 1950s and has been used here and at many other medical centers around the world for diagnostic studies. It has been found to be very safe and effective at finding metastatic lesions. The high resolution of newer PET scanners now allows us to carefully determine how much radiation each metastatic lesion will receive. If 124-I can accurately predict which patients will not respond to 131-I treatments we can then avoid exposing those patients to unnecessary radiation. For the rest of the patients we can custom tailor the 131-I dose to destroy the metastatic lesions.

Condition or disease Intervention/treatment Phase
Thyroid Cancer Radiation: 131 I-iodine (131-I), 124 I-iodine (124-I) Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
Study Start Date : March 2005
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : March 2019

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
131 I-iodine (131-I), 124 I-iodine (124-I)
Radiation: 131 I-iodine (131-I), 124 I-iodine (124-I)
Those who have demonstrated metastases which concentrate radioiodine will undergo routine testing to determine the MTA for blood and lung tissue. This will be performed with 124-I instead of 131-I. If the diagnostic scans (done with 123-I) show that the metastatic lesions concentrate radioiodine, the patient will be treated with 131-I based on standard of care discussions at a tumor board meeting. One week following the 131-I therapy, a whole body scan will be obtained and compared with the 124-I diagnostic scan. One year later, another extent of disease workup will be performed which will include 124-I dosimetry and scanning.

Primary Outcome Measures :
  1. To estimate the relationship between the radiation dose and response to radiation at one year for metastatic lesions arising from differentiated thyroid carcinoma, following a single therapeutic administration of 131-Iodine. [ Time Frame: conclusion of the study ]

Secondary Outcome Measures :
  1. To determine the diagnostic sensitivity of the 124-Iodine whole body scan based on the 131-Iodine post-therapy scan (the "gold-standard"). [ Time Frame: conclusion of the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult thyroid carcinoma patients who have had a total thyroidectomy, histology confirmed by an MSKCC attending pathologist, and radioiodine remnant ablation.
  • Adult thyroid carcinoma patients who have previously demonstrated radioiodine-avid metastases and are about to undergo Thyrogen-assisted dosimetry at MSKCC.
  • The patient and physician are planning to administer 131-I for therapy if persistent radioiodine-avid metastases are present.
  • Men and women of all races, ethnicities, and religious backgrounds are eligible.
  • All subjects must have measurable disease, documented within the previous six months by ultrasonography (US), MRI, or non-contrast CT scanning.

Exclusion Criteria:

  • Thyroid cancer patients who do not have metastases.
  • Thyroid cancer patients who have not demonstrated that their metastases concentrate radioiodine.
  • Patients who are under therapy for other active cancers.
  • Anaplastic or Medullary thyroid carcinoma.
  • Age less than 18 years.
  • Patient who have received a therapeutic dose of radioiodine within the preceding nine months will not be eligible.
  • Patients who plan to withdraw from thyroid hormone prior to dosimetry.
  • Patients who are pregnant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00673010

United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
Principal Investigator: Ravinder Grewal, MD Memorial Sloan Kettering Cancer Center

Additional Information:
Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00673010     History of Changes
Other Study ID Numbers: 04-116
First Posted: May 7, 2008    Key Record Dates
Last Update Posted: February 26, 2018
Last Verified: February 2018

Keywords provided by Memorial Sloan Kettering Cancer Center:

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Neoplasms
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Cadexomer iodine
Anti-Infective Agents, Local
Anti-Infective Agents
Trace Elements
Growth Substances
Physiological Effects of Drugs